IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Provided By GlobeNewswire
Last update: Nov 12, 2024
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer, today reported financial results for the third quarter ended September 30, 2024, and recent corporate highlights.
Read more at globenewswire.com
